Biogen Idec Aims At Alzheimer’s, Adds Proteostasis As Neurodegenerative Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
In a new deal with Proteostasis, Biogen Idec reaffirms its interest in establishing itself in some of the most intractable, hard-to-treat neurodegenerative diseases, such as Parkinson’s and Alzheimer’s.